Wang J, Xiong X J. Current situation and perspectives of clinical study in integrative medicine in China[J]. Evid-Based Complement Alternat Med, 2012, doi: 10.1155/2012/268542.
[3]
Wang J, Xiong X J. Control strategy on hypertension in Chinese medicine[J]. Evid-Based Complement Alternat Med, 2012, doi: 10.1155/2012/284847.
[4]
Wang J, Wang P Q, Xiong X J. Current situation and re-understanding of syndrome and formula syndrome in Chinese medicine[J]. Int Med, 2012, 2(3):15.
[5]
熊兴江,王阶.经方在高血压治疗中的运用[J].中国中药杂志,2013,38(11):1836.
[6]
K A Griffin, A K Bidani. Hypertensive renal damage: insights from animal models and clinical relevance[J]. Curr Hyperten Reports, 2004, 6 (2): 145.
[7]
S Mennuni, S Rubattu, G Pierelli, et al. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage[J]. J Human Hyperten, 2013, doi:10.1038/jhh.2013.55.
[8]
Nissenson A R, Pereira B J, Collions A J, et al. Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization[J]. Am J Kidney Dis, 2001, 37 (6): 1177.
[9]
R Rocha, P N Chander, A Zuckerman, et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats[J]. Hypertension, 1999, 33: 232.
[10]
Zuccheli P, Zuccala A. Recent data on hypertention and progressive renal disease[J]. J Human Hyperten, 1996, 3(10): 679.
[11]
A J Collins, B Kasiske, C Herzog, et al. Excerpts from the United States renal data system 2004 annual data report: atlas of end-stage renal disease in the United States[J]. Am J Kid Dis, 2005, 45 (1): A5.
Fliser D. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease[J]. J Nephrol, 2010, 23(4): 369.
[14]
Kuo H T, Shin S J, Kuo M C, et al. Effects of specific endthelin-1 recepter antagonisis on proliferation and firbonectin production of glomerular mesangial cells stimulated with angiotensin Ⅱ[J]. Kaohsiung J Med Sci, 2006, 22 (8): 371.
[15]
Whitworth J A. Progression of renal failure——the role of hypertension[J]. Annals Academy Med, 2005, 34 (1): 8.
[16]
Tang H T, Cheng D S, Jia Y T, et al. Angiotensin Ⅱinduces type Ⅰcollagen gene expression in human dermal fibrovlasts through an AP-1/TCF-β1-dependent pathway[J]. Biochem Biophys Res Communi, 2009, 385: 418.
[17]
M Suthanthiran, B Li, J O Song, et al. Transforming growth factor-β1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage[J]. National Acad Sci, 2000, 97 (7): 3479.
[18]
P Minuz, P Patrignani, S Gaino, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease[J]. Circulation, 2002, 106: 2800.
[19]
Polichnowski A J, Jin C, Yang C, et al. Role of renal perfusion pressure versus angiotensin Ⅱ on renal oxidative stress in angiotensin Ⅱ-induced hypertensive rats[J]. Hypertension, 2010, 55: 1425.
[20]
Thakur S, Du J, Hourani S, et al. Inactivation of adenosine A2A receptor attenuates basal and angiotensin Ⅱ-induced ROS production by Nox2 in endothelial cells[J]. J Bilo Chem, 2010, 285 (51): 40104.
[21]
Hou X, Shen Y H, Li C, et al. PPAR alpha agonist fenofibrate protects the kidney from hypertensive injuty in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity[J]. Biochem Biophys Res Commun, 2010, 394 (3): 653.
[22]
Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency[J]. N Eng J Med, 1996, 334: 939.
[23]
Hirsch S, Hirsch J, Bhatt U, et al. Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success[J]. Am J Nephrol, 2012, 36: 430.
[24]
Wright J T Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial[J]. J Amer Med Assoc, 2002, 288 (19): 2421.
[25]
Messerli F H, Williams B, Ritz E. Essential hypertension[J]. Lancet, 2007, 370 (9587): 591.
Girerd X, Bureau J M, Hanon O, et al. Study of the effect of season on the frequency of side effects or antihypertensive agents[J]. Arch Mal Coeur Vaiss, 2002, 95 (7/8): 718.
[42]
Grossman E, Messerli F H. High blood pressure. A side effect of drugs, poisons, and food[J]. Arch Intern Med, 1995, 155 (5): 450.
[43]
Seama J C, Schauer D, Kinder, et al. Dialysis adequacy reduces the length of ventilator wean in patients with end stage renal disease and prolonged respiratory failure[J]. Amer J Respirat Criti Care Med, 2010, 181: A3041.
[44]
Bethesda. USRDS 2009 annual data report: atlas of end-stage renal disease in the United States[J]. US Renal Data System, 2009, 4:1256.
[45]
Messerli F H, Williams B, Ritz E. Essential hypertension[J]. Lancet, 2007, 370 (9587): 591.
[46]
C Hawk, H Ndetan, M W Evans. Potential role of complementary and alternative health care providers in chronic disease prevention and health promotion: an analysis of national health interview survey data[J]. Preventive Med, 2012, 54: 18.
Wang J, Xiong X J. Outcome measures of Chinese herbal medicine for hypertension: an overview of systematic reviews[J]. Evid Based Complement Alternat Med, 2012, doi: 10.1155/2012/697237.
Xiong X J, Yang X C, Liu W, et al. Trends in the treatment of hypertension from the perspective of traditional Chinese medicine[J]. Evid Based Complement Alternat Med, 2013, doi: 10.1155/2013/275279.
[56]
Xiong X J, Yang X C, Liu Y M, et al. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science[J]. Hyperten Res, 2013, doi: 10.1038/hr.2013.18.
[57]
王阶,熊兴江,刘巍.补肾法治疗高血压病[J].中国中药杂志,2013,38(9): 1277.
[58]
Wang Jie, Yao Kuiwu, Yang Xiaochen, et al. Chinese patent medicine Liuwei Dihuang wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of random
[59]
Anil K, Bidani, Karen A Griffin. Pathophysiology of hypertensive renal damage implications for therapy[J]. Hypertension, 2004, 44: 595.
[60]
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure[J]. J Amer Med Assoc, 2003, 289: 2560.
[61]
Sciarretta, Sebastianoa, Valenti, et al. Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy-developing education and awareness on microAlbuminuria in patients with hypertensive disease study[J]. J Hyperten, 2010, 28 (2): 251.
[62]
Ruliope L M. The kidney as a sensor of cardiovascular risk in essential hypertension[J]. J Am Soc Nephrol, 2002, 13 (s3): S165.
[63]
USRDS. 2002 annual data report. Atlas of end-stage renal disease in the United States: incidence and prevalence[J]. Am J Kidney Dis, 2003, 41: S41.
[64]
L M Ruilope. The kidney as a sensor of cardiovascular risk in essential hypertension[J]. J Amer Soci Nephrol, 2002, 13 (3): S165.
Li Jing-Xin, Xue Bing, Chai Qiang, et al. Antihypertensive effect of total flavonoid fraction of Astragalus complanatus in hypertensive rats[J]. Chin J Physiol, 2005, 48 (2): 101.
